RBC Capital has increased its price target for Amgen from $400 to $430, reflecting confidence in the biotechnology company's recent strong stock performance. Amgen's shares have outperformed the broader market and its sector, rising 2.6% recently while the S&P 500 declined. Investors are optimistic about Amgen's upcoming quarterly earnings report, with expected earnings per share of $5.69 and revenue of $9.91 billion, both showing growth from the previous year. The raised price target suggests analysts expect continued positive momentum for Amgen's stock.
Amgen trades at USD 401.25 on Pluang as of Oct 08, 2026 22:42 WIB, down 2.86% in the last day despite RBC's raised price target to $430. The stock holds a market cap of $223.32 billion and shows strong investor interest with 81% of Pluang orders to buy. This activity occurs while the company prepares to report earnings, highlighting ongoing market engagement with Amgen shares.
